Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Cements Norovirus Lead Through Vaccine Trial Start

This article was originally published in PharmAsia News

Executive Summary

Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.

You may also be interested in...



Takeda Leads Uncluttered Race For First Norovirus Therapy

Although norovirus infections are implicated in roughly 200,000 deaths per year, there are only four candidates in clinical development, Datamonitor Healthcare notes. This may be due partly to challenges posed by the virus' strain diversity and a lack of epidemiologic data.

Takeda Gains On Sanofi As Two-Shot Dengue Vaccine Advances

While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089582

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel